Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression.
The potential utility of tumour-selective 5-fluorouracil treatment using attenuated Salmonella serovar typhimurium recombinant for cytosine deaminase (TAPET-CD) has been documented in experimental settings. The present data demonstrate that in vivo (19)F-magnetic resonance spectroscopy measurements allow the outcome prediction of this prokaryotic-based therapy, demonstrating the necessity of non-invasive real-time imaging techniques for treatment monitoring.
Dubois
L
L
Department of Radiation Oncology (Maastro Lab), GROW Research Institute, University of Maastricht, UNS 50/23, 6200 MD, Maastricht, The Netherlands.
Dresselaers
T
T
Landuyt
W
W
Paesmans
K
K
Mengesha
A
A
Wouters
B G
BG
Van Hecke
P
P
Theys
J
J
Lambin
P
P
D000818:Animals; D000970:Antineoplastic Agents / Q000032:analysis / Q000378:metabolism* / Q000627:therapeutic use; D015153:Blotting, Western; D002855:Chromatography, Thin Layer; D043525:Cytosine Deaminase / Q000235:genetics / Q000627:therapeutic use*; D005260:Female; D005437:Flucytosine / Q000032:analysis / Q000378:metabolism* / Q000627:therapeutic use; D005472:Fluorouracil / Q000032:analysis / Q000378:metabolism* / Q000627:therapeutic use; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D009374:Neoplasms, Experimental / Q000628:therapy*; D011355:Prodrugs / Q000032:analysis / Q000378:metabolism / Q000627:therapeutic use; D012486:Salmonella typhimurium / Q000235:genetics; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D011355:Prodrugs; D005437:Flucytosine; D043525:Cytosine Deaminase; D005472:Fluorouracil